



SmartPA Criteria Proposal

Drug/Drug Class:	Iron – Injectable Step Therapy Edit
First Implementation Date:	November 19, 2020
Proposed Date:	June 16, 2022
Prepared for:	MO HealthNet
Prepared by:	MO HealthNet/Conduent
Criteria Status:	<input type="checkbox"/> Existing Criteria <input checked="" type="checkbox"/> Revision of Existing Criteria <input type="checkbox"/> New Criteria

Executive Summary

Purpose: Ensure appropriate utilization and control of injectable iron therapy

Why Issue Selected: Iron deficiency anemia is the most common nutritional disorder in the world, accounting for approximately 50% of anemia cases. It is estimated that there are 8–9 million patients in the U.S. who suffer from iron deficiency anemia. Also, the most common reversible cause of chronic anemia or worsening anemia in patients with chronic kidney disease (CKD), other than anemia related directly to CKD, is iron deficiency anemia. Once discovered, the underlying cause of anemia should be treated. Oral iron therapy is used initially to replenish the body’s iron stores; injectable iron therapy may be used in patients who cannot tolerate or absorb the oral agents. Due to the high cost, MO HealthNet will impose clinical criteria to ensure appropriate utilization of injectable iron therapies.

Program-Specific Information:

Date Range FFS 4-1-2021 to 3-31-2022			
Drug	Claims	Spend	Avg Spend per Claim
FERAHEME 510 MG/17 ML VIAL	20	\$14,695.71	\$734.78
FERRLECIT 62.5 MG/5 ML VIAL	2,200	\$31,546.71	\$14.34
INFED 100 MG/2 ML VIAL	522	\$95,399.96	\$182.75
INJECTAFER 750 MG/15 ML VIAL	83	\$59,192.16	\$713.15
INJECTAFER 1,000 MG/20 ML VIAL	0	-	-
MONOFERRIC 1,000 MG/10 ML VIAL	2	\$2,843.22	\$1,421.61
TRIFERIC 27.2 MG/5 ML AMP	0	-	-
TRIFERIC 272 MG PWD PKT	0	-	-
VENOFER 100 MG/5 ML VIAL	11,989	\$667,198.49	\$55.65
VENOFER 200 MG/10 ML VIAL	530	\$39,532.30	\$74.59
VENOFER 50 MG/2.5 ML VIAL	6,982	\$129,745.20	\$18.58

Type of Criteria: Increased risk of ADE Preferred Drug List
 Appropriate Indications Step Therapy Edit

Data Sources: Only Administrative Databases Databases + Prescriber-Supplied

Setting & Population

- Drug class for review: Injectable iron therapy
- Age range: All appropriate MO HealthNet participants

Approval Criteria

- Claim for Ferrlecit, Infed, Triferic, or Venofer **OR**
- Claim for Feraheme, Injectafer, or Monoferric:
 - Documented diagnosis of iron deficiency anemia **AND**
 - Documented adequate therapeutic trial, intolerance, or contraindication to oral iron therapy (defined as 60 days in the past 90 days) **AND**
 - Documented adequate therapeutic trial, intolerance, or contraindication to at least 2 of the following agents: Infed, Ferrlecit, or Venofer (trial defined as 1 claim in the past 90 days) **AND**
 - Participant is dialysis dependent: Feraheme only
 - **For Feraheme or Monoferric: Participant aged 18 years or older**

Denial Criteria

- Therapy will be denied if no approval criteria are met
- Claim for Injectafer or Monoferric: participant is dialysis dependant
- Claim exceeds approved dosing limitations:
 - Feraheme: 34 ml per 25 days
 - Injectafer 750 mg/15 ml vial: 30 ml per 25 days
 - **Injectafer 1,000 mg/20 ml vial: 20 ml per 25 days**
 - Monoferric: 10 ml per 25 days

Required Documentation

Laboratory Results:
MedWatch Form:

<input type="checkbox"/>
<input type="checkbox"/>

Progress Notes:
Other:

<input type="checkbox"/>
<input checked="" type="checkbox"/>

Disposition of Edit

Denial: Exception code "0681" (Step Therapy)
Rule Type: CE

Default Approval Period

6 months

References

- Injectafer® (ferric carboxymaltose injection) [package insert]. Shirley, NY: American Regent, Inc.; November 2021.
- Feraheme® (ferumoxytol injection) [package insert]. Waltham, MA: AMAG Pharmaceuticals, Inc.; September 2020.
- Monoferric® (ferric derisomaltose) [package insert]. Morristown, NJ: Pharmacosmos Therapeutics Inc.; February 2022.

SmartPA Clinical Proposal Form

© 2022 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.

- KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. *Kidney Int Suppl* 2012; 2:279-335. <https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-Anemia-Guideline-English.pdf>
- Short M, et al. Iron Deficiency Anemia: Evaluation and Management. *Am Fam Physician*. 2013;87(2):98-104. <https://www.aafp.org/afp/2013/0115/p98.html>
- IPD Analytics. Hematologic: Iron Deficiency/Replacement. Accessed May 5, 2022.
- Facts & Comparisons. Iron Parenteral. Accessed May 5, 2022.

DRAFT